Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecobalamine for Pain in Fibromyalgia
NCT05008042Phase 2Completed
- Sponsor
- Linnaeus University
- Start
- Feb 2019
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in fibromyalgia (FM) comparing Mecobalamine with Placebo (2 arms). Primary endpoint: Tolerance time at 24 weeks. Started Feb 2019; status: completed.
02
Drugs
mecobalamin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT05008042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008042.